Scientists improved understanding of preclinical Alzheimer’s Disease (AD) – study review by BIOMEDICA CRO
A new study led by investigators at Massachusetts General Hospital (MGH) shows the impact of early amyloid-β and tau protein accumulation on disrupting connections between brain structures that are important for memory.
To learn more about this phenomenon, Yakeel Quiroz, Ph.D., an investigator in the departments of psychiatry and neurology, and colleagues used positron emission tomography (PET) for tau and amyloid-β, and functional magnetic resonance imaging (fMRI) to study how AD pathologies related to connectivity of brain regions and networks in individuals from a large family of more than 6,000 living members with Alzheimer’s Disease.
Quiroz said: “We know now that a lot of things are happening in the brain of those at risk for Alzheimer’s Disease, even before signs of memory impairment, so we hope findings like these can improve our understanding of preclinical Alzheimer’s Disease and help improve the selection of those who would benefit the most from participating in clinical trials.”
The researchers hope this insight will instill a level of urgency and importance in preclinical and clinical trials for Alzheimer’s Disease, particularly those targeting disease prevention.
Please find more information on the Proceedings of the National Academy of Sciences website, research article, “Amyloid-β and tau pathologies relate to distinctive brain dysconnectomics in preclinical autosomal-dominant Alzheimer’s disease”.
BIOMEDICA CRO is honored to participate in preclinical trials, research on new biomarkers and screening tests.
We have a good neuroscience database of clinical sites and are ready to cover investigators` needs in the collection of various human biospecimens and data for research.
BIOMEDICA CRO can provide specimens from Alzheimer’s Disease patients and donors with other different neurological disorders like Multiple Sclerosis, Stroke, Schizophrenia, Anxiety and Panic Disorders, Post-traumatic Stress Syndrome, etc.
Also, we have contracted 50+ sites and departments with other disease areas.
Please email us at office@biomedica-cro.com / LinkedIn to receive high-quality human biospecimens and associated data for your studies.
